SI BONE : June 2022 Investor Presentation

Corporate Overview

June 2022

Safe Harbor Statement

This presentation contains "forward-looking statements," which are statements related to events, results, activities or developments that SI-BONE expects, believes or anticipates will or may occur in the future. Forward-looking often contain words such as "intends," "estimates," "anticipates," "hopes," "projects," "plans," "expects," "seek," "believes," "see," "should," "will," "would," "target," and similar expressions and the negative versions thereof. Such statements are based on SI-BONE's experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances, and speak only as of the date made. Forward-looking statements are inherently uncertain and actual results may differ materially from assumptions, estimates or expectations reflected or contained in the forward-looking statements as a result of various factors. For details on the uncertainties that may cause our actual results to be materially different than those expressed in our forward-looking statements, please review our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, especially the information contained in the section captioned "Risk Factors". We undertake no obligation to publicly update or revise any forward-looking statements to reflect new information or future events or otherwise unless required by law.

2

Transforming & Leading the Sacropelvic Space

Market	Differentiated	Clinical and	Expanding
Leadership	Platform	Educational Focus	Addressable Markets
$2.4B U.S. annual SIJF	5-year SIJF clinical data	SI-BONE SImulator™	Trauma pelvic ring fracture
opportunity		advanced training platform	solution
279K U.S. annual SIJF	Universal U.S. SIJF payor	>2,800 surgeons performed	$350M U.S. annual trauma
procedures opportunity	coverage	procedure since inception	opportunity2
>70,000 procedures	160+ dedicated field	~200 academic programs	Adult deformity spino-
worldwide since inception	representatives	with training events	pelvic fixation/fusion
Majority U.S. SIJF market	Sacropelvic product	~1,100 trained fellows	$250M U.S. annual
share1	portfolio & pipeline	and residents	deformity opportunity2

1. Spinemarket, Inc. (2021)
2. Based on management estimate.

3

Setup to Deliver Strong and Sustainable Long-term Growth

▪ iFuse launch		▪	iFuse-TORQlaunch
		▪	iFuse Bedrock Granite - FDA BDD
▪	Bedrock launch	▪	SALLY Clinical Trial (2-yrdata)

• iFuse 3D launch

• LOIS clinical Trial (5-yrdata)

2009	2015	2017	2018	2019	2020	2021	2022
	▪ SIFI Clinical Trial		IPO	▪ SI SImulator introduced	▪ iFuse Bedrock Granite -

▪ INSITE Clinical Trial

• Product / solutions launched
• Clinical trial results

launch & NTAP

▪ iFuse-TORQ - fragility fracture FDA clearance

Near Universal coverage in the U.S. for MIS SIJF

4

Second Quarter of 2022 Performance Summary

$25.6M	~86%	ACTIVE SURGEON BASE
720
WORLDWIDE	GROSS
REVENUE	MARGIN

~15%	160+	640
YTD R&D	DEDICATED
INVESTMENT 1	SALES FORCE	2Q21	2Q22

Note: As of quarter ended June 30, 2022. 1. As a percent of YTD revenue

5